Key result
Factor V-Leiden mutation is ~25 percentage points more common in DVT patients under 50.
Why the study?
What is the incidence of Factor V-Leiden mutation among Lebanese patients with lower extremity deep venous thrombosis and conditions suggestive of hypercoagulation states, particularly comparing patients younger than 50 years to those older than 50 years?
Cohort (n=283)
No
What is the incidence of Factor V-Leiden mutation among Lebanese patients with lower extremity deep venous thrombosis and conditions suggestive of hypercoagulation states, particularly comparing patients younger than 50 years to those older than 50 years?
Answers are grounded in this paper and cite their sources.
Due to the high prevalence of Factor V-Leiden in Lebanon, over half of DVT patients with hypercoagulable risk factors—and more than two-thirds of those under age 50—harbor the mutation, supporting targeted thrombophilia screening in young and high-risk patients in high-prevalence populations.
Aim. Lebanon exhibits one of the highest prevalences of factor V-Leiden (FVL) in the world (14.4%). The aim of this study is to evaluate the incidence of FVL mutation among Lebanese patients with lower extremity venous thrombosis. Material and Methods. From January 2003 to January 2011, 283 consecutive Lebanese patients, diagnosed with deep venous thrombosis (DVT) by duplex scan, were retrospectively reviewed. FVL mutation was tested among patients with conditions highly suggestive of hypercoagulation states (65 patients). Results. FVL mutation was detected among 56.9% of patients, 68.6% of patients younger than 50 years, and 43.4% of patients older than 50 years (P = 0.041). FVL mutation was commonly reported in young adults, in patients with pregnancy, estrogen drugs, recurrent DVT, and resistance to anticoagulation. Conclusion. The high rate of FVL mutation observed among Lebanese patients with venous thrombosis is related to the high prevalence of this mutation in the Lebanese population. Thrombophilia screening should be tailored to accommodate a population's risk factor. In countries with high prevalence of FVL, this mutation should be screened among patients younger than 50 years and patients with situations highly suggestive of hypercoagulation states.
No takes yet. Share an insight, caveat, or question.
Raghid Kreidy (2012) conducted a cohort in Lower extremity deep venous thrombosis (n=283). Age <50 years among DVT patients with high-risk hypercoagulable conditions vs. Age >50 years among DVT patients with high-risk hypercoagulable conditions was evaluated on Incidence of Factor V-Leiden mutation among tested patients (p=0.041). Factor V-Leiden mutation was detected in 56.9% of tested Lebanese DVT patients and was more common in patients <50 years than >50 years.
Synapse has enriched 10 related papers. Consider them for comparative context: